Celgene Corp (CELG) 110.51 $CELG
Final Glance: Biotechnology companies
AP - 22 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), CELG: 110.51 (-1.42)
Watch for Celgene to Potentially Rebound After Falling 1.27% Yesterday
Comtex SmarTrend(R) - 1 hr 13 mins ago
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $109.46 to a high of $113.50. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $111.51 on volume of 5.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 110.51 (-1.42)
Celgene Set to Possibly Rebound After Yesterday's Selloff of 1.27%
Comtex SmarTrend(R) - 1 hr 14 mins ago
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $109.46 to a high of $113.50. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $111.51 on volume of 5.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 110.51 (-1.42)
Public Shame for Biotechs Not Webcasting 'JPM15' Breakout Sessions
at The Street - Tue Jan 06, 2:08PM CST
In a blow to investor transparency, an embarrassingly small number of healthcare companies are webcasting their Q&A breakout sessions at next week's J.P. Morgan Healthcare Conference.
BLUE: 95.24 (+3.19), BIIB: 334.65 (-2.09), VRTX: 117.36 (-3.67), ISIS: 65.44 (-2.73), SGEN: 31.45 (-1.60), GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), AGIO: 111.43 (+2.56), BMY: 58.48 (-0.10), CELG: 110.51 (-1.42)
Midday Glance: Biotechnology companies
AP - Tue Jan 06, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), CELG: 110.51 (-1.42)
Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
at The Street - Tue Jan 06, 10:52AM CST
TheStreet's Adam Feuerstein lays down his predictions for the biotech industry for 2015.
BLUE: 95.24 (+3.19), BIIB: 334.65 (-2.09), QCOR: 93.60 (+1.52), ISIS: 65.44 (-2.73), GILD: 97.65 (+0.86), PFE: 31.42 (+0.26), VVUS: 2.94 (-0.10), JUNO: 51.66 (+5.71), BMY: 58.48 (-0.10), MNKD: 5.57 (-0.13), ARNA: 3.32 (-0.20), PBYI: 188.12 (-0.25), CELG: 110.51 (-1.42)
Cramer: Gilead 'Back in the Driver's Seat' After CVS Deal
at The Street - Tue Jan 06, 10:04AM CST
TheStreet's Jim Cramer says Gilead Sciences is attractive given its large cash position, low valuation and recent deal with CVS Health.
BIIB: 334.65 (-2.09), ESRX: 83.28 (-0.94), GILD: 97.65 (+0.86), CVS: 94.23 (+0.07), ABBV: 64.33 (-0.32), REGN: 396.89 (-15.58), CELG: 110.51 (-1.42)
Early Glance: Biotechnology companies
AP - Tue Jan 06, 9:37AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), CELG: 110.51 (-1.42)
Biotechs to Follow in 2015 off Fresh Insider Moves
ACCESSWIRE - Tue Jan 06, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2015 / Insider moves are always interesting to equity traders no matter where they occur, but more than any other sector, insider buys tend to inspire the most chatter around biotech. This is mostly due to the esoteric science and trial statistics that often determine the fate of a firm, which company and other biotech insiders tend to know more about than even premium hedge fund operators.
ADXS: 7.99 (-0.68), SGEN: 31.45 (-1.60), GILD: 97.65 (+0.86), OPK: 9.91 (-0.15), MRK: 60.32 (+2.28), IBB: 300.81 (-5.04), AGIO: 111.43 (+2.56), TEVA: 54.93 (-0.16), CELG: 110.51 (-1.42)
Celgene Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Tue Jan 06, 7:30AM CST
During the 33rd Annual J.P. Morgan Healthcare Conference on January 12, 2015 at 10:30 a.m. ET, Celgene Corporation (NASDAQ:CELG) will present a business update on the Company in addition to unaudited 2014 financial results and an updated financial outlook. The presentation can be accessed live by webcast and the financial data will be made available in the Investor Relations section of the Company's website at www.celgene.com.
JPM: 58.98 (-1.57), CELG: 110.51 (-1.42), CELGZ: 3.16 (+0.02)
After CAR-T: Getting Ahead of the Next Hot Trend in Cancer Stocks
at The Street - Tue Jan 06, 7:30AM CST
Here's how investors can help fund the next cure for cancer: anti-CD47 antibody therapies.
BLUE: 95.24 (+3.19), KITE: 71.45 (+1.70), JUNO: 51.66 (+5.71), TRIL: 11.12 (+1.57), CELG: 110.51 (-1.42)
Making Celgene A Core Holding Should Be Better Than Trading In And Out Of It
Abba's Aces - at Seeking Alpha - Tue Jan 06, 7:19AM CST
SPY: 199.82 (-1.90), CELG: 110.51 (-1.42)
Does Pfizer Inc. Stock Offer a Market-Crushing Opportunity in 2015?
George Budwell, The Motley Fool - Motley Fool - Tue Jan 06, 6:47AM CST
Source: Flickr via Montgomery County Planning Commission As the world's largest pharmaceutical company, Pfizer rarely inspires investors seeking high-growth opportunities. Indeed, its stock has performed rather poorly compared to the broader...
ZTS: 42.63 (-0.42), ACT: 255.17 (-1.52), AZN: 68.16 (-1.70), PFE: 31.42 (+0.26), TEVA: 54.93 (-0.16), ABBV: 64.33 (-0.32), NVS: 91.67 (-0.78), CELG: 110.51 (-1.42)
My 2014 Best Performers, Looking Ahead To 2015
Michael J. Bernard - at Seeking Alpha - Tue Jan 06, 6:34AM CST
KMI: 40.83 (-0.82), MMM: 158.65 (-1.71), PRGO: 164.60 (-0.31), LMT: 188.40 (-0.89), DUK: 84.20 (+1.36), LO: 62.57 (+0.09), SDRL: 10.48 (-0.33), SRE: 109.01 (-1.03), INTC: 35.28 (-0.67), ANH: 5.24 (unch), QCOM: 72.88 (-1.05), AMAT: 23.25 (-0.91), NAT: 10.69 (+0.46), ABBV: 64.33 (-0.32), FL: 54.44 (-1.45), MSFT: 45.65 (-0.68), AAPL: 106.26 (+0.01), UNP: 112.23 (-2.37), RAI: 63.44 (+0.24), FRO: 3.16 (+0.60), NSC: 103.00 (-3.39), CYS: 8.91 (+0.02), MO: 48.98 (+0.29), CSX: 33.49 (-1.39), SO: 49.75 (+0.59), HRZN: 13.98 (unch), CELG: 110.51 (-1.42), WBA: 74.69 (+0.19), AB: 24.63 (-0.58), CTB: 33.93 (+0.06), CNI: 65.11 (-0.85), AZN: 68.16 (-1.70), MGA: 104.05 (-2.30), ULTA: 126.95 (-0.20), CP: 177.08 (-3.95), KLAC: 66.69 (-2.03), BRK.B: 146.84 (-0.16)
Cramer Says Wells Fargo Is a Buy; Wait for a Regeneron Pullback
at The Street - Mon Jan 05, 10:21AM CST
TheStreet's Jim Cramer likes Wells Fargo for its low valuation, while Regeneron will be a buy on a pullback because of its growth potential.
WFC: 52.09 (-1.11), REGN: 396.89 (-15.58), CELG: 110.51 (-1.42)
Should Celgene Corporation Be a Staple in Long-Term Portfolios?
Todd Campbell, The Motley Fool - Motley Fool - Mon Jan 05, 8:33AM CST
Source Celgene. Celgene 's latest outlook for the next few years projects that sales will roughly double between 2013 and 2017. If Celgene delivers on that rosy outlook, investors might find including this biotech in long-haul investment...
BLUE: 95.24 (+3.19), AGIO: 111.43 (+2.56), CELG: 110.51 (-1.42)
3 Biotech Stocks We're Watching Closest Ahead of the JPMorgan Healthcare Conference
Motley Fool Staff - Motley Fool - Mon Jan 05, 6:52AM CST
Source: GlaxoSmithKline via Flickr. When it comes to healthcare events, there is none more important than the JPMorgan Healthcare Conference. Filled with dozens upon dozens of biotech and medical device companies, the JPMorgan Healthcare...
JPM: 58.98 (-1.57), ICPT: 160.01 (-16.99), GSK: 41.68 (-0.23), FOLD: 8.26 (-0.51), CELG: 110.51 (-1.42)
Growth Stocks 2015: 3 Companies With Room to Run
George Budwell, The Motley Fool - Motley Fool - Sun Jan 04, 9:17AM CST
Growth stocks should be an integral part of any well-balanced portfolio. But discovering companies with decent growth prospects and whose shares aren't grossly overvalued is easier said than done. The fact is that most growth stocks garner huge...
BLUE: 95.24 (+3.19), ESRX: 83.28 (-0.94), GILD: 97.65 (+0.86), PFE: 31.42 (+0.26), ABBV: 64.33 (-0.32), CELG: 110.51 (-1.42)
How These 3 Stocks Doubled Investors' Money in Q4
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 03, 9:31AM CST
Source: Flickr user Tax Credits Most of the time, life-changing financial gains are generated over the long haul, not in the blink of an eye. However, sometimes stocks can put up jaw-dropping returns over a short period of time too. For example,...
BLUE: 95.24 (+3.19), ISIS: 65.44 (-2.73), ALNY: 94.02 (-1.36), OVAS: 47.18 (-0.08), GILD: 97.65 (+0.86), RGLS: 15.68 (-0.56), CELG: 110.51 (-1.42)
Final Glance: Biotechnology companies
AP - 22 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), CELG: 110.51 (-1.42)
Watch for Celgene to Potentially Rebound After Falling 1.27% Yesterday
Comtex SmarTrend(R) - 1 hr 13 mins ago
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $109.46 to a high of $113.50. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $111.51 on volume of 5.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 110.51 (-1.42)
Celgene Set to Possibly Rebound After Yesterday's Selloff of 1.27%
Comtex SmarTrend(R) - 1 hr 14 mins ago
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $109.46 to a high of $113.50. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $111.51 on volume of 5.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 110.51 (-1.42)
Public Shame for Biotechs Not Webcasting 'JPM15' Breakout Sessions
at The Street - Tue Jan 06, 2:08PM CST
In a blow to investor transparency, an embarrassingly small number of healthcare companies are webcasting their Q&A breakout sessions at next week's J.P. Morgan Healthcare Conference.
BLUE: 95.24 (+3.19), BIIB: 334.65 (-2.09), VRTX: 117.36 (-3.67), ISIS: 65.44 (-2.73), SGEN: 31.45 (-1.60), GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), AGIO: 111.43 (+2.56), BMY: 58.48 (-0.10), CELG: 110.51 (-1.42)
Midday Glance: Biotechnology companies
AP - Tue Jan 06, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), CELG: 110.51 (-1.42)
Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
at The Street - Tue Jan 06, 10:52AM CST
TheStreet's Adam Feuerstein lays down his predictions for the biotech industry for 2015.
BLUE: 95.24 (+3.19), BIIB: 334.65 (-2.09), QCOR: 93.60 (+1.52), ISIS: 65.44 (-2.73), GILD: 97.65 (+0.86), PFE: 31.42 (+0.26), VVUS: 2.94 (-0.10), JUNO: 51.66 (+5.71), BMY: 58.48 (-0.10), MNKD: 5.57 (-0.13), ARNA: 3.32 (-0.20), PBYI: 188.12 (-0.25), CELG: 110.51 (-1.42)
Cramer: Gilead 'Back in the Driver's Seat' After CVS Deal
at The Street - Tue Jan 06, 10:04AM CST
TheStreet's Jim Cramer says Gilead Sciences is attractive given its large cash position, low valuation and recent deal with CVS Health.
BIIB: 334.65 (-2.09), ESRX: 83.28 (-0.94), GILD: 97.65 (+0.86), CVS: 94.23 (+0.07), ABBV: 64.33 (-0.32), REGN: 396.89 (-15.58), CELG: 110.51 (-1.42)
Early Glance: Biotechnology companies
AP - Tue Jan 06, 9:37AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), CELG: 110.51 (-1.42)
Biotechs to Follow in 2015 off Fresh Insider Moves
ACCESSWIRE - Tue Jan 06, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2015 / Insider moves are always interesting to equity traders no matter where they occur, but more than any other sector, insider buys tend to inspire the most chatter around biotech. This is mostly due to the esoteric science and trial statistics that often determine the fate of a firm, which company and other biotech insiders tend to know more about than even premium hedge fund operators.
ADXS: 7.99 (-0.68), SGEN: 31.45 (-1.60), GILD: 97.65 (+0.86), OPK: 9.91 (-0.15), MRK: 60.32 (+2.28), IBB: 300.81 (-5.04), AGIO: 111.43 (+2.56), TEVA: 54.93 (-0.16), CELG: 110.51 (-1.42)
Celgene Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Tue Jan 06, 7:30AM CST
During the 33rd Annual J.P. Morgan Healthcare Conference on January 12, 2015 at 10:30 a.m. ET, Celgene Corporation (NASDAQ:CELG) will present a business update on the Company in addition to unaudited 2014 financial results and an updated financial outlook. The presentation can be accessed live by webcast and the financial data will be made available in the Investor Relations section of the Company's website at www.celgene.com.
JPM: 58.98 (-1.57), CELG: 110.51 (-1.42), CELGZ: 3.16 (+0.02)
After CAR-T: Getting Ahead of the Next Hot Trend in Cancer Stocks
at The Street - Tue Jan 06, 7:30AM CST
Here's how investors can help fund the next cure for cancer: anti-CD47 antibody therapies.
BLUE: 95.24 (+3.19), KITE: 71.45 (+1.70), JUNO: 51.66 (+5.71), TRIL: 11.12 (+1.57), CELG: 110.51 (-1.42)
Making Celgene A Core Holding Should Be Better Than Trading In And Out Of It
Abba's Aces - at Seeking Alpha - Tue Jan 06, 7:19AM CST
SPY: 199.82 (-1.90), CELG: 110.51 (-1.42)
Does Pfizer Inc. Stock Offer a Market-Crushing Opportunity in 2015?
George Budwell, The Motley Fool - Motley Fool - Tue Jan 06, 6:47AM CST
Source: Flickr via Montgomery County Planning Commission As the world's largest pharmaceutical company, Pfizer rarely inspires investors seeking high-growth opportunities. Indeed, its stock has performed rather poorly compared to the broader...
ZTS: 42.63 (-0.42), ACT: 255.17 (-1.52), AZN: 68.16 (-1.70), PFE: 31.42 (+0.26), TEVA: 54.93 (-0.16), ABBV: 64.33 (-0.32), NVS: 91.67 (-0.78), CELG: 110.51 (-1.42)
My 2014 Best Performers, Looking Ahead To 2015
Michael J. Bernard - at Seeking Alpha - Tue Jan 06, 6:34AM CST
KMI: 40.83 (-0.82), MMM: 158.65 (-1.71), PRGO: 164.60 (-0.31), LMT: 188.40 (-0.89), DUK: 84.20 (+1.36), LO: 62.57 (+0.09), SDRL: 10.48 (-0.33), SRE: 109.01 (-1.03), INTC: 35.28 (-0.67), ANH: 5.24 (unch), QCOM: 72.88 (-1.05), AMAT: 23.25 (-0.91), NAT: 10.69 (+0.46), ABBV: 64.33 (-0.32), FL: 54.44 (-1.45), MSFT: 45.65 (-0.68), AAPL: 106.26 (+0.01), UNP: 112.23 (-2.37), RAI: 63.44 (+0.24), FRO: 3.16 (+0.60), NSC: 103.00 (-3.39), CYS: 8.91 (+0.02), MO: 48.98 (+0.29), CSX: 33.49 (-1.39), SO: 49.75 (+0.59), HRZN: 13.98 (unch), CELG: 110.51 (-1.42), WBA: 74.69 (+0.19), AB: 24.63 (-0.58), CTB: 33.93 (+0.06), CNI: 65.11 (-0.85), AZN: 68.16 (-1.70), MGA: 104.05 (-2.30), ULTA: 126.95 (-0.20), CP: 177.08 (-3.95), KLAC: 66.69 (-2.03), BRK.B: 146.84 (-0.16)
Cramer Says Wells Fargo Is a Buy; Wait for a Regeneron Pullback
at The Street - Mon Jan 05, 10:21AM CST
TheStreet's Jim Cramer likes Wells Fargo for its low valuation, while Regeneron will be a buy on a pullback because of its growth potential.
WFC: 52.09 (-1.11), REGN: 396.89 (-15.58), CELG: 110.51 (-1.42)
Should Celgene Corporation Be a Staple in Long-Term Portfolios?
Todd Campbell, The Motley Fool - Motley Fool - Mon Jan 05, 8:33AM CST
Source Celgene. Celgene 's latest outlook for the next few years projects that sales will roughly double between 2013 and 2017. If Celgene delivers on that rosy outlook, investors might find including this biotech in long-haul investment...
BLUE: 95.24 (+3.19), AGIO: 111.43 (+2.56), CELG: 110.51 (-1.42)
3 Biotech Stocks We're Watching Closest Ahead of the JPMorgan Healthcare Conference
Motley Fool Staff - Motley Fool - Mon Jan 05, 6:52AM CST
Source: GlaxoSmithKline via Flickr. When it comes to healthcare events, there is none more important than the JPMorgan Healthcare Conference. Filled with dozens upon dozens of biotech and medical device companies, the JPMorgan Healthcare...
JPM: 58.98 (-1.57), ICPT: 160.01 (-16.99), GSK: 41.68 (-0.23), FOLD: 8.26 (-0.51), CELG: 110.51 (-1.42)
Growth Stocks 2015: 3 Companies With Room to Run
George Budwell, The Motley Fool - Motley Fool - Sun Jan 04, 9:17AM CST
Growth stocks should be an integral part of any well-balanced portfolio. But discovering companies with decent growth prospects and whose shares aren't grossly overvalued is easier said than done. The fact is that most growth stocks garner huge...
BLUE: 95.24 (+3.19), ESRX: 83.28 (-0.94), GILD: 97.65 (+0.86), PFE: 31.42 (+0.26), ABBV: 64.33 (-0.32), CELG: 110.51 (-1.42)
How These 3 Stocks Doubled Investors' Money in Q4
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 03, 9:31AM CST
Source: Flickr user Tax Credits Most of the time, life-changing financial gains are generated over the long haul, not in the blink of an eye. However, sometimes stocks can put up jaw-dropping returns over a short period of time too. For example,...
BLUE: 95.24 (+3.19), ISIS: 65.44 (-2.73), ALNY: 94.02 (-1.36), OVAS: 47.18 (-0.08), GILD: 97.65 (+0.86), RGLS: 15.68 (-0.56), CELG: 110.51 (-1.42)
